Covenant Health’s Cumberland Medical Center was the first in East Tennessee to introduce new robotic technology powered by ...

Caris Life Sciences® , a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing ...

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

Federal health officials are quietly moving to overhaul the fine print on testosterone replacement therapy, a shift that ...

Outside of her job as the therapist on the series “Couples Therapy,” she has a favorite clip of the rapper performing and ...

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

Rat disease models have played an integral role in scientific discovery and cancer research, including Nobel Prize–winning ...

The study is aimed at advancing personalized cancer treatment by exploring a personalized approach to radioligand therapy.

NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) ...

GE HealthCare GEHC has announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment ...

The partnership will evaluate whether imaging- and biomarker-informed insights can support a more personalised approach to ...